In a chaotic Thursday session at the Centers for Disease Control and Prevention, the agency’s Advisory Committee on Immunization Practices (ACIP) postponed a scheduled vote on changes to the hepatitis B vaccine recommendation until Friday morning. The meeting, held in the CDC’s broadcast studio under bright lights and cameras, featured disputed presentations and confusion over voting language that prompted the delay. The panel, reshaped in June after Health Secretary Robert F. Kennedy Jr. dismissed earlier members, debated whether to change a 34-year-old policy that advises a first hepatitis B dose within 24 hours of birth. Organizers cited disagreement and unclear ballot wording as the proximate reasons for moving the vote.
Key takeaways
- ACIP delayed a Thursday vote on hepatitis B vaccine guidance to Friday morning because members disagreed about and were confused by the voting language.
- For 34 years, CDC guidance has recommended a first hepatitis B vaccine dose for newborns within 24 hours of birth; the panel considered narrowing that to a discussion-based approach for mothers who test negative.
- A CDC analysis covering children born from 1994 to 2023 estimated hepatitis B vaccination prevented more than 6 million infections and nearly 1 million hospitalizations.
- The meeting featured presenters described in official notes as anti-vaccine activists and a climate scientist who has written in anti-vaccine outlets, rather than CDC medical subject-matter staff.
- Several presenters questioned vaccine safety or efficacy; ACIP-affiliated clinicians and outside public health experts pushed back, citing decades of safety data.
- The session took place in the CDC broadcast studio to “accommodate increased public interest,” according to an HHS spokesperson, a departure from ACIP’s usual conference-room format.
- Sen. Bill Cassidy (R-La.), a liver physician and Senate health committee chair, criticized the panel as “totally discredited” on social media before the meeting; other medical leaders called parts of the session “political theater.”
Background
ACIP is the federal advisory committee that recommends who should receive vaccines and when, combining epidemiology, safety data and programmatic considerations. For decades, ACIP reviews new vaccines and new indications; it historically has relied on CDC vaccine safety and disease-burden presentations to inform votes. The current debate centers on a practice the CDC has endorsed for 34 years—administering the first hepatitis B vaccine dose to newborns within 24 hours of life to prevent perinatal transmission.
Hepatitis B is a viral infection that can progress to chronic liver disease, cancer and death. Transmission from an infected mother to her infant during delivery is a well-documented route of spread; not all pregnant people receive or complete testing for hepatitis B markers. Public-health models and surveillance data have long supported newborn vaccination as a primary prevention strategy to block early-life infections that carry lifetime risk.
Main event
The meeting opened in the CDC’s broadcast studio with bright lighting and large cameras in view—an atypical setting for ACIP deliberations. Organizers said the venue change was intended to accommodate heightened interest, but several participants and observers said the setting created the feel of a spectator event rather than a technical advisory session. Presentations included two individuals identified by meeting materials as anti-vaccine activists and a climate scientist who has written for outlets critical of vaccines; CDC medical staff did not deliver the primary safety and efficacy briefings typical of past votes.
During the safety discussion, Mark Blaxill—described in materials as a businessman and recent CDC hire without medical credentials—suggested that symptoms reported in some infants after vaccination could be “possibly connected” to encephalitis. Dr. Cody Meissner, the only ACIP member with prior committee service in attendance, explicitly disputed that characterization, saying the symptoms were not encephalitis and that such a linkage was not something a practicing physician would make.
As the session moved toward a vote, several committee members signaled they did not understand the resolution’s wording. Dr. Joseph Hibbeln quipped that the language might have been drafted by a “department of redundancy,” and other members requested clarifying edits. The committee chair, Dr. Kirk Milhoan, was absent for the postponement; Vice chair Dr. Robert Malone cited Milhoan’s imminent travel to Asia as the reason he was not present for later deliberations.
Analysis & implications
The episode underscores tension between a long-standing, evidence-based vaccination policy and a reconstituted advisory panel whose roster and witnesses have raised concerns among mainstream public-health experts. If ACIP were to narrow the newborn-dose recommendation, it would mark a major policy shift away from decades of consensus and could reduce the coverage that has driven dramatic declines in perinatal hepatitis B transmission. That outcome could disproportionately affect infants born to people who were not screened or who acquired infection late in pregnancy.
Public confidence in routine immunization depends on both clear, consistent recommendations and transparent scientific processes. The use of nontraditional presenters and a high‑production venue fueled perceptions among clinicians and professional societies that the meeting prioritized spectacle over systematic evidence review, a criticism expressed by the American College of Physicians’ president during the session.
Policy change would also have practical programmatic consequences: delaying or deferring the birth dose requires expanded prenatal screening and reliable follow-up systems to ensure infants receive timely protection. Health systems and birthing centers would need protocols to counsel families and track vaccine uptake—tasks that are more complex and resource‑intensive than sustaining the current universal birth‑dose practice.
Comparison & data
| Policy | Current CDC Guidance | Proposed ACIP Change (under consideration) |
|---|---|---|
| Newborn hepatitis B dose | Administer first dose within 24 hours of birth (34 years) | Recommend shared decision-making for mothers who test negative, with possible deferral of birth dose |
| Population impact (1994–2023) | Estimated prevention of >6 million infections and ~1 million hospitalizations (CDC analysis) | Potential for increased perinatal infections if coverage drops and prenatal testing gaps persist |
The table contrasts the longstanding universal birth-dose policy with the narrower approach under discussion. CDC modeling across births from 1994 to 2023 attributes millions of prevented infections and hundreds of thousands of hospitalizations to hepatitis B vaccination programs; reducing early-life coverage could reverse some of those gains, especially where prenatal screening and follow-up are incomplete.
Reactions & quotes
“You are wasting taxpayer dollars by not having scientific, rigorous discussion on issues that truly matter.”
Dr. Jason Goldman, American College of Physicians
“That is absolutely not encephalitis. That’s not a statement that a physician would make.”
Dr. Cody Meissner, ACIP member
“[The advisory panel is] totally discredited” and “not protecting children.”
Sen. Bill Cassidy (R-La.) — social media post
Unconfirmed
- Claims that the constellation of post-vaccine infant symptoms reported in anecdotally selected cases constitutes encephalitis remain unsupported by clinical diagnostic data presented at the meeting.
- Assertions at the session that the hepatitis B vaccine lacks long-term safety or effectiveness contradict extensive published surveillance and were not substantiated with comprehensive, peer-reviewed analyses during the hearing.
Bottom line
The delay of the hepatitis B vote reflects substantive procedural and evidentiary disputes on an advisory committee that has recently been reconstituted. At stake is a narrow, high‑impact public-health policy: the universal birth dose has been a cornerstone of perinatal hepatitis B prevention for 34 years and is credited with preventing millions of infections.
Any change that reduces routine newborn dosing would require robust compensating systems—expanded prenatal screening, reliable counseling and guaranteed follow-up—that public-health infrastructure does not uniformly provide. Observers should watch the Friday session for clarified language, the final vote outcome, and whether CDC subject-matter experts provide the comprehensive safety and effectiveness reviews that standard ACIP practice has required.